Sažetak sa skupa
https://doi.org/10.26800/LV-145-supl2-CR80
USE OF IMMUNOTHERAPY IN THE TREATMENT OF A PATIENT WITH TWO SIMULTANEOUS METASTATIC DISEASES
Matej Penava
; School of Medicine, University of Zagreb, Zagreb, Croatia
Anđelo Kurtin
Katarina Čular
Tajana Silovski
Sažetak
Immunotherapy is an evolving and promising cancer treatment proven to significantly prolong survival in a multitude of oncological diseases. Nivolumab, a monoclonal antibody to the PD-1 receptor, is an immunotherapy used in the treatment of several cancers, including melanoma and renal cell carcinoma (RCC).
Ključne riječi
Immunotherapy; Metastatic disease; Nivolumab
Hrčak ID:
304024
URI
Datum izdavanja:
23.4.2023.
Posjeta: 245 *